Prednisone (NSC-10023)

Catalog No.S1622 Synonyms: Adasone

For research use only.

Prednisone (NSC-10023, Adasone) is a synthetic corticosteroid agent that is particularly effective as an immunosuppressant compound.

Prednisone (NSC-10023) Chemical Structure

CAS No. 53-03-2

Selleck's Prednisone (NSC-10023) has been cited by 6 Publications

Purity & Quality Control

Choose Selective Glucocorticoid Receptor Inhibitors

Biological Activity

Description Prednisone (NSC-10023, Adasone) is a synthetic corticosteroid agent that is particularly effective as an immunosuppressant compound.
Glucocorticoid receptor [1]
In vitro

Prednisone blocks Peripheral blood lymphocytes (PBL) growth in the G1 phase of cell cycle and inhibits both IL-2 receptor (IL-2R) expression and IL-2 secretion in activated human peripheral blood T lymphocytes. Prednisone increases apoptosis in PHA-activated human PBL, and the apoptotic effect of Prednisone is stronger on CD8(+) than on CD4(+) T lymphocytes. [1]

In vivo Prednisone-treated rats show a significant delay of 20% in learning and memory retention in rats as compared with controls. [2] Prednisone results in reduced weight gain, unchanged alter uterine weight, lowered serum magnesium (Mg), unchange serum calcium (Ca), phosphate (P), 25-hydroxyvitamin D (25OHD), or 1,25-dihydroxyvitamin D [1,25(OH)2D], striking increased in calcified cartilage, reduced cross-sectional area and cortical area, unchange medullary area of the tibial diaphysis, lowered periosteal and endocortical bone formation and apposition rates, increased mean cancellous bone area and cancellous bone perimeter of the tibial metaphysis in both sham-operated and ovariectomized rats. [3] Prednisone-treated rabbit shows a 30% reduction in percent stenosis, a 35% decrease in neointimal area, and a 66% decrement in neointimal thickness. [4] Prednisone treatment significantly reduces the level of TGF-beta1 and HYP in diaphragm from mdx mice to values similar to control mice, but results in a higher level of the HP cross-link compared with untreated mdx mice. [5]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 358.43


CAS No. 53-03-2
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC12CC(=O)C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03673748 Not yet recruiting Drug: Mesenchymal stromal cells (MSC)|Drug: Placebo Lupus Nephritis|Lupus Erythematosus Red de Terapia Celular|Hospital del Río Hortega|Hospital Clínico Universitario de Valladolid|University of Valladolid December 2022 Phase 2
NCT05379634 Recruiting Drug: Nipocalimab|Other: Placebo|Drug: Glucocorticoids Myositis Janssen Research & Development LLC July 15 2022 Phase 2
NCT04972760 Not yet recruiting Drug: Baricitinib|Drug: Placebo Dermatomyositis Assistance Publique - Hôpitaux de Paris June 15 2022 Phase 3
NCT04965636 Not yet recruiting Drug: Mepolizumab Hypereosinophilic Syndrome GlaxoSmithKline June 30 2022 Phase 3

(data from, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Prednisone (NSC-10023) | Prednisone (NSC-10023) supplier | purchase Prednisone (NSC-10023) | Prednisone (NSC-10023) cost | Prednisone (NSC-10023) manufacturer | order Prednisone (NSC-10023) | Prednisone (NSC-10023) distributor